European Urology Focus

Slides:

Advertisements

Similar presentations

Volume 56, Issue 5, Pages (November 2009)

Advertisements

European Urology Focus

Volume 72, Issue 1, Pages (July 2017)

Volume 59, Issue 2, Pages (February 2011)

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 2, Pages (August 2015)

Volume 68, Issue 6, Pages (December 2015)

Volume 69, Issue 3, Pages (March 2016)

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 58, Issue 5, Pages (November 2010)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 72, Issue 1, Pages (July 2017)

Volume 71, Issue 1, Pages (January 2017)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 51, Issue 4, Pages (April 2007)

Volume 70, Issue 4, Pages (October 2016)

The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer

Volume 52, Issue 3, Pages (September 2007)

PETER R. CARROLL, MD, JOSEPH C. PRESTI, MD

Volume 68, Issue 1, Pages (July 2015)

Volume 59, Issue 2, Pages (February 2011)

Volume 53, Issue 4, Pages (April 2008)

Towards Early and More Specific Diagnosis of Prostate Cancer

Prostate Cancer Detection: A View of the Future

Diagnostic Strategies for Prostate Cancer

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 184, Issue 4, Pages (October 2010)

Volume 56, Issue 2, Pages (August 2009)

Volume 71, Issue 6, Pages (June 2017)

Volume 73, Issue 4, Pages (April 2018)

Volume 66, Issue 5, Pages (November 2014)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volume 62, Issue 4, Pages (October 2012)

Volume 63, Issue 3, Pages (March 2013)

Volume 65, Issue 6, Pages (June 2014)

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 72, Issue 4, Pages (October 2017)

European Urology Oncology

European Urology Oncology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Volume 72, Issue 1, Pages (July 2017)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review Alexey Surov, Hans Jonas Meyer, Andreas.

Volume 74, Issue 6, Pages (December 2018)

Apoorva R. Vashi, M.D., Joseph E. Oesterling, M.D.

European Urology Oncology

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 54, Issue 5, Pages (November 2008)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 74, Issue 6, Pages (December 2018)

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Does PSA Testing Influence the Natural History of Prostate Cancer?

European Urology Oncology

Presentation transcript:

European Urology Focus The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing Martin Eklund, Tobias Nordström, Markus Aly, Jan Adolfsson, Peter Wiklund, Yvonne Brandberg, James Thompson, Fredrik Wiklund, Johan Lindberg, Joseph C. Presti, Mark StLezin, Mark Clements, Lars Egevad, Henrik Grönberg European Urology Focus DOI: 10.1016/j.euf.2016.10.009 Copyright © 2016 Terms and Conditions

Fig. 1 Comparison of Gleason Score ≥7 detection rate and biopsy results in different prostate-specific antigen (PSA) ranges for Current Prostate Cancer Testing (CPT) and Stockholm-3 Model (S3M), respectively. CI=confidence interval; GS=Gleason Score. European Urology Focus DOI: (10.1016/j.euf.2016.10.009) Copyright © 2016 Terms and Conditions